Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Dimethyl fumarate treatment in relapsed and refractory cutaneous T-cell lymphoma: a multicenter phase 2 study

Jan P. Nicolay, Susanne Melchers, Jana D. Albrecht, Chalid Assaf, Edgar Dippel, Rudolf Stadler, Ulrike Wehkamp, Marion Wobser, Jing Zhao, Ina Burghaus, Sven Schneider, Karsten Gülow, Sergij Goerdt, Christian M. Schürch, Jochen S. Utikal, Peter H. Krammer

Blood (2023) 142 (9): 794–805.

https://doi.org/10.1182/blood.2022018669

Published: 2023

Includes: Supplemental data

Journal Articles

Combined inhibition of Bcl-2 and NFκB synergistically induces cell death in cutaneous T-cell lymphoma

Tabea C. Froehlich, Karin Müller-Decker, Jana D. Braun, Thomas Albrecht, Anne Schroeder, Karsten Gülow, Sergij Goerdt, Peter H. Krammer, Jan P. Nicolay

Blood (2019) 134 (5): 445–455.

https://doi.org/10.1182/blood.2019001545

Published: 2019

Includes: Supplemental data

Journal Articles

Dimethyl fumarate restores apoptosis sensitivity and inhibits tumor growth and metastasis in CTCL by targeting NF-κB

Jan P. Nicolay, Karin Müller-Decker, Anne Schroeder, Markus Brechmann, Markus Möbs, Cyrill Géraud, Chalid Assaf, Sergij Goerdt, Peter H. Krammer, Karsten Gülow

Blood (2016) 128 (6): 805–815.

https://doi.org/10.1182/blood-2016-01-694117

Published: 2016

Includes: Supplemental data

Journal Articles

High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade

Michael K. Kießling, Patrick A. Oberholzer, Chandrani Mondal, Maria B. Karpova, Marie C. Zipser, William M. Lin, Michael Girardi, Laura E. MacConaill, Sarah M. Kehoe, Charlie Hatton, Lars E. French, Levi A. Garraway, Gernot Polier, Dorothee Süss, Claus-Detlev Klemke, Peter H. Krammer, Karsten Gülow, Reinhard Dummer

Blood (2011) 117 (8): 2433–2440.

https://doi.org/10.1182/blood-2010-09-305128

Published: 2011

Includes: Supplemental data

Journal Articles

Wogonin preferentially kills malignant lymphocytes and suppresses T-cell tumor growth by inducing PLCγ1- and Ca 2+ -dependent apoptosis

Sven Baumann, Stefanie C. Fas, Marco Giaisi, Wolfgang W. Müller, Anette Merling, Karsten Gülow, Lutz Edler, Peter H. Krammer, Min Li-Weber

Blood (2008) 111 (4): 2354–2363.

https://doi.org/10.1182/blood-2007-06-096198

Published: 2008

NARROW

Dimethyl fumarate treatment in relapsed and refractory cutaneous T-cell lymphoma: a multicenter phase 2 study

Combined inhibition of Bcl-2 and NFκB synergistically induces cell death in cutaneous T-cell lymphoma

Dimethyl fumarate restores apoptosis sensitivity and inhibits tumor growth and metastasis in CTCL by targeting NF-κB

High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade

Wogonin preferentially kills malignant lymphocytes and suppresses T-cell tumor growth by inducing PLCγ1- and Ca 2+ -dependent apoptosis

Email alerts

ASH Publications

American Society of Hematology

Dimethyl fumarate treatment in relapsed and refractory cutaneous T-cell lymphoma: a multicenter phase 2 study

Combined inhibition of Bcl-2 and NFκB synergistically induces cell death in cutaneous T-cell lymphoma

Dimethyl fumarate restores apoptosis sensitivity and inhibits tumor growth and metastasis in CTCL by targeting NF-κB

High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade

Wogonin preferentially kills malignant lymphocytes and suppresses T-cell tumor growth by inducing PLCγ1- and Ca 2+ -dependent apoptosis

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only